Melissa Badamo

DocwireNews

Pediatric patients with sickle cell disease (SCD) have higher health care resource use and costs than matched controls without SCD, according to a recent study.The study was led by Giovanna Barcelos, of Pfizer, and presented at the 2024 American Society of Pediatric Hematology/Oncology Conference held April 3&ndash;6, 2024, in Seattle, Washington.A total of 1,299 patients and 1,299 controls were retrospectively identified from the International Business Machines (IBM&reg;) MarketScan&reg; Commercial Database, then matched 1:1 for age, gender, US region, and race. The patients were younger than 18 years old (median, 10 years old), commercially insured, and had three or more inpatient or outpatient SCD diagnoses.The patients had a median follow-up of 35.1 months, while the controls had a median follow-up of 33.5 months. During the follow-up, 34.9% of patients received hydroxyurea, 23.0% received at least one blood transfusion, and 61.3% received an opioid pain medication. Complications included vaso-occlusive crisis (70.8% of patients vs 0% of controls) and retinopathy (6.5% of patients vs 0% of controls).Per year, the SCD group had more inpatient hospitalizations, outpatient visits, emergency room visits, prescriptions, and longer length of stay than the control group. For the SCD cohort, the mean costs per year were also higher across all health care resource use categories: inpatient costs ($15,195 vs $477, respectively), outpatient costs including emergency room ($12,746 vs $1,758, respectively), and pharmacy costs ($3,504 vs $610, respectively), for a total of $31,445 for patients and $2,844 for controls (all P&lt; 0.0001).The total out-of-pocket costs per person per year was $2,071 for patients, compared with $489 for controls (P &lt; 0.0001).&ldquo;This study excluded children without commercial insurance, who may have higher burden; however, the results highlight the substantial economic burden of pediatric patients with SCD enrolled in US commercial insurance plans,&rdquo; the researchers concluded.Funding for this study was provided by Pfizer.ReferenceBarcelos G, Peixoto T, Alvir J, et al. &ldquo;Economic burden of sickle cell disease for children in the United States with commercial insurance.&rdquo; Poster #105. Presented at the 2024 American Society of Pediatric Hematology/Oncology Conference; April 3&ndash;6, 2024; Seattle, Washington.

Eva Blondeaux, MD

Risk-Reducing Surgery Linked to Survival in Young BRCA Carriers

Genetics & Breast Cancer

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

Latest News

What Are the Health Care Resource Costs for US Pediatric Patients With SCD?

Sickle Cell Disease

The study compared health care resource use and costs of pediatric patients with SCD compared with matched controls.

What Are the Health Care Resource Costs for US Pediatric Patients With Sickle Cell Disease?

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe